Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study

Journal of Gastrointestinal Oncology

article

Jian Zhai¹  Jianwei Liu²  Zhigang Fu¹  Shilei Bai²  Xiaowei Li¹  Zengqiang Qu¹  Yanfu Sun²  Ruiliang Ge³  Feng Xue² 

[1] Department II of Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Naval Medical University;Department of Hepatic Surgery II, Eastern Hepatobiliary Surgery Hospital, Naval Medical University;Department of Outpatient, Eastern Hepatobiliary Surgery Hospital, Naval Medical University

关键词: Hepatocellular carcinoma (HCC);    targeted drugs;    regorafenib;    efficacy;   

DOI  :  10.21037/jgo-22-404

学科分类：肿瘤学

来源: Pioneer Bioscience Publishing Company

【 摘 要 】

Background: There is lack of studies on sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma (HCC). This study was to explore the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib failure in HCC patients. Methods: This study was a retrospective, real-world study that included 50 HCC patients who received sequential regrafinib after sorafenib and lenvatinib failure. The safety and prognosis of two groups were compared. Results: 0.05). On long-term prognosis, total overall survival (TOS) in sorafenib and lenvatinib group were 23.0 (95% CI: 15.1–30.9) vs. 29.7 (95% CI: 21.4–38.1) months. The difference was statistically significant (P=0.041). Besides, regorafenib overall survival (ROS) in sorafenib and lenvatinib group were 11.7 (95% CI: 7.1–16.3) vs. 15.9 (95% CI: 8.3–23.5) months. The difference was statistically significant ( P=0.045). The regorafenib progression-free survival (RPFS) was 5.6 (95% CI: 1.9–9.2) vs. 8.0 (95% CI: 5.1–10.9) months in sorafenib and lenvatinib group, respectively, and difference was not statistically significant (P=0.380). Conclusions: Regorafenib is an effective drug for second-line treatment of HCC, with fewer severe adverse events, ORR and DCR was 14–22% and 62–60%, respectively. Both TOS and ROS in lenvatinib group were better than those in sorafenib group. For HCC patients whose first-line targeted drug is lenvatinib, it is safe and effective to accept regorafenib after disease progresses.

【 授权许可】

Unknown